CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
Verapamildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06447688
NCT06447688Phase 4Completed

The Role of Oral Verapamil in Preventing Radial Spasm During Transradial Angiography

Mersin Medicalpark Hastanesi·interventional·Posted Jun 7, 2024·Updated Oct 10, 2025

In Brief

A Phase 4 clinical trial evaluating Verapamil for Radial Artery Spasm. Completed, enrolled 150 participants across 1 site.

Detailed Summary

Coronary angiography (CAG) is an invasive imaging method performed to determine the degree of coronary artery disease. Radial artery spasm (RAS) is one of the most common complications during coronary angiography performed via the transradial approach, causing patient discomfort or sometimes interrupting the procedure. There are many studies on RAS, and various pharmacoagents administered intravenously (intraarterial) to prevent RAS have been described. However, there is limited data in the literature regarding oral pharmacoagents that will prevent this complication. In our study, the preventive effect of Verapamil, given orally 2 hours before coronary angiography, on radial artery spasm will be investigated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

Phase 4CompletedFinished
20252026
First PostedJun 7, 2024
Enrollment StartJun 5, 2024
Primary CompletionNov 1, 2024
Study CompletionNov 15, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.1 years ago

Interventions

Verapamildrug

Prevent